Biosimilars

Biosimilars

Pfenex is utilizing its PfÄ“nex Expression Technology™ to build a comprehensive portfolio of biosimilar molecules. No advantages are gained by simply repeating an innovator’s protein expression and bioprocess strategy that may have been developed more than 20 years ago. Pfenex applies its parallel processing, toolbox approach to production strain development to arrive at a highly advantaged expression strain and bioprocess. Capitalizing on the cost effectiveness of Pfenex's technology-based processes and the proven ability to rapidly identify a robust production strain, Pfenex has been able to develop a comprehensive pipeline of  nine potential biosimiliar products.